搜索:   联系我们 |  English 


    发布时间:2018-10-18 09:51:27    点击:853

学术报告


题  目:Is there a cure for chronic/metabolic diseases?
报告人:Zemin Yao教授
单  位: Department of Biochemistry, Microbiology, and Immunology, Ottawa Institute of Systems Biology, University of Ottawa
地  点:化学楼H201蒋雯若报告厅
时  间:2018年10月25号(星期四)上午10:00
联系人:刘震 教授
 
摘要:
Chronic/metabolic diseases encompass a broad spectrum of metabolic abnormalities that are associated with ageing, nutrient overload, and diminished physical activities. The manifestation of such abnormalities can occur in different parts of the body. At cellular level, metabolic abnormalities are often associated with excessive accumulation of protein/lipid substances within the cells, which, we observed, results in an impairment of motility of endo-lysosomes. Our work intended to restore the normal intracellular movement of endo-lysosomes therefore correcting the dysregulated nutrient utilization and energy imbalance. To this end, we have identified several small GTPases, as druggable targets, that play a pivotal role in restoring endo-lysosome motility and lysosomal function under metabolically stressed conditions. Administration of recombinant DNA encoding such a GTPase in mice could effectively (within days) ameliorate diet-induced obesity, hepatosteatosis, and diabetic dyslipidemia. The utility of restoring endo-lysosome motility through targeting small GTPase in the treatment of other chronic/metabolic diseases, including neurodegenerative diseases (e.g. Parkinson’s disease and Alzheimer’s disease) is currently being explored. Our work thus suggests strongly that small GTPases are valid druggable targets for the treatment of chronic/metabolic diseases.
 
简历:
Dr Yao, Professor of Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, obtained his BSc in Biology at East China Normal University (Shanghai, China), MSc and PhD in Biochemistry at University of British Columbia (Vancouver, Canada). After PDF training at the Gladstone Institute of Cardiovascular Disease (UCSF), Dr Yao was appointed as Assistant Professor at Department of Biochemistry, University of Alberta and as Staff Scientist at University of Ottawa Heart Institute. From 2002 through 2013, Dr Yao served as Chairman of the Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa. Dr Yao is renowned for his research centered on lipid and lipoprotein metabolism, mainly on lipid and protein factors that regulate, intracellularly, the assembly and secretion of triglyceride-rich VLDL1. He has systematically analyzed structural domains within apoB100 and apoC3 that are essential for triglyceride recruitment during VLDL1 assembly and secretion. He has also investigated the involvement of LRP1, calcium-independent phospholipase, hepatic lipase, lipin1, and various small GTPases in different aspects of lipid and lipoprotein metabolism in the liver. Currently, Dr Yao is a visiting professor of Shanghai University of Traditional Chinese Medicine and Guangzhou University of Chinese Medicine. He is a Co-Funder and President of Motigenix Inc., and a consultant of ModernaTX Inc.
 
 
生命分析化学国家重点实验室

地址:江苏省南京市栖霞区仙林大道163号南京大学化学楼    邮编:210023    电话:86-25-89682304   传真:86-25-89687761

© 2010-2018   南京大学 化学化工学院